Clinical trial · Interventional
Study of Nesvacumab (REGN910/ SAR307746)
A Phase 1 Study of REGN910 Administered Every 2 Weeks in Patients With Advanced Solid Malignancies
NCT01271972CI-TRIAL-00018277completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open-label, multicenter, ascending, multiple dose study of nesvacumab (REGN910/ SAR307746) administered IV every 2 weeks.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| nesvacumab (REGN910/ SAR307746) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (7)
- type
- EXPERIMENTAL
- label
- Cohort 1
- description
- Dose 1
- interventionNames
- Drug: nesvacumab (REGN910/ SAR307746)
- type
- EXPERIMENTAL
- label
- Cohort 2
- description
- Dose 2
- interventionNames
- Drug: nesvacumab (REGN910/ SAR307746)
- type
- EXPERIMENTAL
- label
- Cohort 3
- description
- Dose 3
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Confirmed diagnosis of advanced solid malignancy. 2. ECOG performance status 0 - 1 3. Adequate hepatic, renal and bone marrow function 4. At least 3 weeks since last dose of chemotherapy, hormonal therapy or radiotherapy 5. At least 6 weeks since last dose of bevacizumab 6. At least 4 weeks since last surgery 7. At least 4 weeks since last dose of investigational treatment Exclusion Criteria: 1. Patients with brain metastases, spinal cord compression, carcinomatous meningitis, or other evidence of central nervous system involvement 2. Patients with serious non healing wound or acute ulcer 3. Either systolic blood pressure \>150 mm Hg or diastolic blood pressure \>95 mm Hg 4. Patients with medical history of myocardial infarction, unstable angina pectoris, coronary/ peripheral artery bypass graft, congestive heart failure or ventricular arrhythmia 5. Patients with deep vein thrombosis or pulmonary embolism within last 6 months
References
Publications (0)
Data not yet available
No reference posted for this study.